Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis

Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1(6):457–62.

CAS  Article  Google Scholar 

Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469–75.

CAS  Article  Google Scholar 

FDA. Immunogenicity testing of therapeutic protein products — developing and validating assays for anti-drug antibody detection. 2019.

EMA. Guideline on immunogenicity assessment of therapeutic proteins. 2017.

Gupta S, Devanarayan V, Finco D, Gunn GR 3rd, Kirshner S, Richards S, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55(5):878–88.

CAS  Article  Google Scholar 

Jolicoeur P, Tacey RL. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis. 2012;4(24):2959–70.

CAS  Article  Google Scholar 

Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol. 2007;49(3):230–7.

CAS  Article  Google Scholar 

Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods. 2006;308(1–2):101–8.

CAS  Article  Google Scholar 

Xu W, Jiang H, Titsch C, Haulenbeek JR, Pillutla RC, Aubry AF, et al. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. J Immunol Methods. 2015;416:94–104.

CAS  Article  Google Scholar 

Xu W, Cummings J, Sank M, Juhel M, Li X, Gleason C, et al. Development and validation of a functional cell-based neutralizing antibody assay for ipilimumab. Bioanalysis. 2018;10(16):1273–87.

CAS  Article  Google Scholar 

Sun D, Hsu A, Quiroz J, He X, Whiteman MC, Gurney KB, et al. Development and comparison of three cell-based potency assays for anti-respiratory syncytial virus monoclonal antibody. Biologicals. 2021.

Tang A, Chen Z, Cox KS, Su HP, Callahan C, Fridman A, et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019;10(1):4153.

Article  Google Scholar 

Aliprantis AO, Wolford D, Caro L, Maas BM, Ma H, Montgomery DL, et al. A phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults. Clin Pharmacol Drug Dev. 2021;10(5):556–66.

CAS  Article  Google Scholar 

Maas BM, Lommerse J, Plock N, Railkar RA, Cheung SYA, Caro L, et al. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. EBioMedicine. 2021;73: 103651.

CAS  Article  Google Scholar 

Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53.

Hacimustafaoglu M, Celebi S, Aynaci E, Sinirtas M, Koksal N, Kucukerdogan A, et al. The progression of maternal RSV antibodies in the offspring. Arch Dis Child. 2004;89(1):52–3.

CAS  Article  Google Scholar 

Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, et al. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine. 2022;40(3):450–8.

Article  Google Scholar 

Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018;37(9):886–92.

Article  Google Scholar 

Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003;21(24):3479–82.

Article  Google Scholar 

Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol. 2009;123(2):398–403.

Article  Google Scholar 

Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis. 1998;177(2):463–6.

CAS  Article  Google Scholar 

留言 (0)

沒有登入
gif